لخّصلي

Dr.Many compounds exhibit synergistic activity in the investigated cancer cell lines where Dasatinib and the WEE1 kinase inhibitor MK-1775 seemed to be promising candidates for further investigations.During his work at the Molecular Medicine Institute, Dr. Hmeidat explored novel molecularly targeted combination therapies for squamous carcinoma of the head and neck cancer.

Dr. Ali Hmeidat gained a scholarship from the German Academic Exchange Service
(DAAD) under the program of Short-Term Research Grants to continue his research
at Martin Luther University in Germany.
This DAAD grant is awarded to young scientists and academics wishing to carry out
research and continue their education in Germany for up to 6 months. During his
work at the Molecular Medicine Institute, Dr. Hmeidat explored novel molecularly
targeted combination therapies for squamous carcinoma of the head and neck
cancer. High-throughput screens using FDA-approved drugs were performed to
discover possible synergistic candidates for the treatment of head and neck cancer.
Many compounds exhibit synergistic activity in the investigated cancer cell lines
where Dasatinib and the WEE1 kinase inhibitor MK-1775 seemed to be promising
candidates for further investigations.